CDK inhibitors in hormone receptor positive advanced breast cancer
نویسندگان
چکیده
Endocrine treatment is the current first line treatment in ER+ advanced breast cancer with a requirement of predictive biomarkers to the treatment and different approaches for endocrine resistance risk. Cyclin dependent kinases (CDKs) are regulating each step of cellular division in mammalian cell cycle and are hyperactivated in cancer cells causing cancer progression. Next generation pan-CDK inhibitors are in clinical development, while clinical trials in breast cancer, particularly in ER+ subtype where the greatest growth inhibition has been observed. Here I will review the data from this new class of drugs.
منابع مشابه
Fulvestrant in advanced breast cancer: evidence to date and place in therapy
Breast cancer is a classical hormone-dependent tumour; therefore, endocrine therapy is the mainstay of treatment for hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer. Until recently, classical endocrine agents such as tamoxifen, steroidal and nonsteroidal aromatase inhibitors and fulvestrant have been widely used in postmenopausal patients to treat loca...
متن کاملOvercoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors
Dysregulation of the cyclin D and cyclin-dependent kinase (CDK) pathway in cancer cells may inhibit senescence and promote cellular proliferation. By using various different mechanisms, malignant cells may increase cyclin D-dependent activity. The cyclin D-cyclin-dependent kinases 4 and 6 (CDK4/6)-retinoblastoma (Rb) pathway controls the cell cycle restriction point, and is commonly dysregulate...
متن کاملIncorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.
After optimizing endocrine monotherapy modalities in the setting of advanced luminal breast cancer (BC), dual endocrine/targeted therapy combinations have been tested with positive results, and are transforming this BC subtype treatment landscape. Cell cycle deregulation is a hallmark of cancer that has become a key druggable target in hormone receptor (HR)-positive BC due to its role in endocr...
متن کاملInhibition of the Cyclin-Dependent Kinases (CDK) 4/6 as Therapy for Estrogen Receptor Positive Breast Cancer
Endocrine therapy (ET) is the usual first-line therapy for patients with hormone receptor-positive metastatic breast cancer (HR+MBC). However, resistance to ET frequently occurs during the course of treatment. Cellular pathways involved in cell proliferation are targets for new drugs that interfere with development of resistance to ET. Cyclin-dependent kinases (CDKs) are a subgroup of serine/ t...
متن کاملHR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
BACKGROUND Cyclin-dependent kinase (CDK) 4/6 inhibitor-based therapies have shown great promise in improving clinical outcomes for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. OBJECTIVES 1. Discuss the mode of action of the three CDK4/6 inhibitors in late clinical development: palbociclib (PD-0332991; Pfizer),...
متن کامل